Corporate ActionJun 29, 2026, 06:07 AM
Decoy Therapeutics Secures Up to $21M Private Placement Financing
AI Summary
Decoy Therapeutics Inc. announced a private placement financing expected to generate approximately $3.5 million in initial gross proceeds. The financing includes the sale of 592,217 shares or pre-funded warrants at $5.91 per share, along with milestone-based Series A, B, and C warrants. If fully exercised upon achieving clinical milestones and stockholder approval, these warrants could provide up to an additional $17.5 million, bringing the total potential gross proceeds to $21 million. The company plans to use the net proceeds for general corporate purposes, including advancing its lead asset into clinical trials.
Key Highlights
- Initial gross proceeds from private placement: approximately $3.5 million.
- Potential additional gross proceeds from milestone warrants: up to $17.5 million.
- Total potential gross proceeds from financing: up to $21 million.
- Sale of 592,217 shares or pre-funded warrants at $5.91 per share.
- Series A warrants linked to Phase 1 clinical trial, potential $3.5 million.
- Series B warrants linked to Phase 2a human challenge trial approval, potential $7.0 million.
- Series C warrants linked to positive Phase 2a data, potential $7.0 million.
- Stockholder approval required for milestone warrant exercise.
Price Impact
More from DCOY
More in Corporate Action